OraSure Technologies, Inc. (NASDAQ:OSUR) Shares Sold by Murphy Pohlad Asset Management LLC

Murphy Pohlad Asset Management LLC cut its stake in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 5.4% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 80,287 shares of the medical instruments supplier’s stock after selling 4,563 shares during the period. Murphy Pohlad Asset Management LLC’s holdings in OraSure Technologies were worth $343,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in OSUR. Creative Planning acquired a new stake in shares of OraSure Technologies in the third quarter valued at about $54,000. SG Americas Securities LLC acquired a new stake in shares of OraSure Technologies in the first quarter valued at about $72,000. Mackenzie Financial Corp acquired a new stake in shares of OraSure Technologies in the second quarter valued at about $72,000. Tocqueville Asset Management L.P. raised its position in shares of OraSure Technologies by 20.0% in the first quarter. Tocqueville Asset Management L.P. now owns 15,089 shares of the medical instruments supplier’s stock valued at $93,000 after buying an additional 2,512 shares during the last quarter. Finally, Shikiar Asset Management Inc. acquired a new stake in shares of OraSure Technologies in the second quarter valued at about $96,000. 93.50% of the stock is currently owned by institutional investors and hedge funds.

OraSure Technologies Trading Up 2.6 %

OraSure Technologies stock opened at $4.17 on Friday. OraSure Technologies, Inc. has a 12-month low of $3.91 and a 12-month high of $8.45. The stock has a market cap of $310.96 million, a P/E ratio of 11.58 and a beta of 0.05. The company has a 50-day moving average price of $4.23 and a 200 day moving average price of $4.49.

OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings data on Tuesday, August 6th. The medical instruments supplier reported $0.03 earnings per share (EPS) for the quarter. OraSure Technologies had a net margin of 9.88% and a return on equity of 9.15%. The firm had revenue of $54.34 million during the quarter, compared to analysts’ expectations of $53.35 million. As a group, analysts forecast that OraSure Technologies, Inc. will post -0.11 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. Evercore ISI increased their target price on shares of OraSure Technologies from $4.50 to $5.00 and gave the company an “in-line” rating in a research report on Wednesday, August 7th. StockNews.com upgraded shares of OraSure Technologies from a “hold” rating to a “buy” rating in a research report on Friday, October 4th. Two investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $6.67.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.